Erratum: The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: A retrospective analysis (Cancer Chemotherapy and Pharmacology DOI: 10.1007/s00280-007-0473-0);The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: A retrospective analysis

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 1, 2008, Pages 167-175

  Fine, Robert L ^a,g   Fogelman, David R ^a   Schreibman, Stephen M ^b   Desai, Manisha ^c   Sherman, William ^a   Strauss, James ^d   Guba, Susan ^e   Andrade, Riolan ^f   Chabot, John ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b MORRISTOWN MEMORIAL HOSPITAL   (United States)

^c US Oncology Associates ^*  (United States)

^d Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^e Texas Cancer Center   (United States)

^f Hematology Oncology Associates   (United States)

^g NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOCETAXEL; GEMCITABINE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG MECHANISM; EFFUSION; FATIGUE; FEMALE; HUMAN; HUMAN CELL; INFECTION; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; PANCREAS CANCER; PANCREATICODUODENECTOMY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RETROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; THRUSH; TREATMENT FAILURE; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

EID: 34848896905     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0569-6     Document Type: Erratum

References (35)

1. Jemal A, Murray T, Samuels A (2003) Cancer statistics, 2003. CA-Cancer J Clin 53:5-26
2. Burris HA, Moore MJ, Anderson J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Onc 15(6):2403-2413
3. Brand R, Capadano M, Tempero M (1997) A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15(4):331-341
4. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Onc 21(18):3402-3408
5. Moore M, Goldstein D, Hamm J et al (2005) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol 23:1s, (Suppl, Abstr 1)
6. Cunningham D, Chau I, Stocken D, Barletta E, Moscetti L, Recchia F et al Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer Suppl 4, Abstr. PS 11
7. Fine RL, Fogelman DR, Sherman W et al (2003) The GTX regimen: A biochemically synergistic combination for advanced pancreatic cancer (PC). Proc Am Soc Clin Onc Abstr #1129
8. Fine RL, Fogelman DR, Schreibman S, Guba S, Sharma J, Shapiro G (2004) GTX chemotherapy for metastatic pancreatic cancer: Response, survival, and toxicity data. J Clin Oncol 22:381s suppl. Abstr #4271
9. Sherman WH, Fine RL (2001) Combination gemcitabine and docetaxel in advanced adenocarcinoma of the pancreas. Oncology 60(4):316-321
10. Hess V, Salzberg M, Borner M et al (2003) Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: A phase I/II trial. J Clin Oncol 21(1):66-68
11. Fogelman DR, Sherman W, Schreibman S, Fine RL (2003) Effective salvage chemotherapy with minimal toxicity for relapsed, advanced pancreatic cancer. Proc Am Soc Clin Onc Abstr #1517
12. Fogelman D, Fine RL, Schreibman S (2004) Effective salvage therapy (T-GX) for pancreatic cancer patients after chemotherapy with GTX. J Clin Oncol 22:380s suppl. Abstr #4268
13. Khorana A, Fine RL (2004) Pancreatic cancer and thromboembolic disease. Lancet Oncol 5(11):655-663
14. Poplin E, Levy D, Berlin J et al (2006) Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin(GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 24(18):2006, LBA 4004
15. Cartwright TH, Cohn A, Varkey JA et al (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20(1):160-164
16. Stathopoulos GP, Syrigos K, Polyzos A et al (2004) Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol 15:224-229
17. Hermann R, Bodoky G, Ruhstaller T et al (2005) Gemcitabine (G) plus capecitabine versus G alone in advanced/metastatic pancreatic cancer. A randomized phase III study of the SAKK and CECOG groups, Proc Am Soc Clin Oncol Abst #4010
18. Rougier P, Adenis A, Dureux M et al (2000) A phase II study: Docetaxel as first line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 36:1016-1025
19. Androulakis N, Kourousis C, Dimopoulos M (1999) Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II trial. J Clin Oncol 17:1779-1785
20. Schneider BP, Ganjoo KN, Seitz DE et al (2003) Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 65(3):218-223
21. Louvet C et al (2004) Gemcitabine versus GEMOX (gemcitabine + oxaliplatin) in non resectable pancreatic adenocarcinoma: Final results of the GERCOR /GISCAD Intergroup Phase III. J Clin Oncol 22:315s suppl, abstr #4008
22. Heineman V, Quietzsch D, Gieseler F (2003) A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma, Proc Am Soc Clin Oncol Abst #1003
23. Rocha Lima CM, Rotche R, Jeffrey M et al (2003) A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. Proc Am Soc Clin Onc Abst #1005
24. Kozuch P, Grossbard ML, Barzdins A et al (2001) Irinotecan Combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory pancreatic cancer. Oncologist 6(6):488-495
25. El-Rayes BF, Zalupski MM, Shields AF et al (2003) Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 15(1):2920-2925
26. Araneo M, Bruckner HW, Grossbard ML et al (2003) Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin and cisplatin (GFP): A highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. Cancer Invest 21(4):489-496
27. CALGB News, http://www.calgb.org/index.php?action=fullnews&id = 28; or http://www.calgb.org website
28. Kindler HL, Bylow KA, Hochster HS et al (2006) A randomized phase III study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis. J Clin Onc 24(18S):A4040
29. Berlin JD, Adak S, Vaughn DJ et al (2000) A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group study (E3296). Oncology 58:215-218
30. Berlin JD, Catalano P, Thomas J et al (2002) Phase III study of gemcitabine with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275
31. Reiss H, Helm A, Niedergethmann M et al (2005) Randomized, prospective multicenter phase III trial of gemcitabine, 5FU, folinic acid versus gemcitabine alone in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol Abst #4009
32. Hidalgo M, Castellano D, Paz-Ares L et al (1999) Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17(2):585-592
33. Fine RL, Fogelman DR, Sherman W et al (2006) Gemcitabine, Docetaxel, and Capecitabine (GTX) in the treatment of metastatic pancreatic cancer (PC): A prospective phase II Study. Proc Am Soc Clin Oncol Abst #14024
34. Sawada N, Ishikawa T, Fukase Y et al (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/docetaxel in human cancer xenografts. Clin Cancer Res Suppl 4(4):1013-1019
35. Fogelman DR, Chen J, Chabot J, Allendorf J, Schreibman S, Ennis R, Fine RL (2004) The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: From 5-FU to GTX. Surg Oncol Clin No Am 13:711-735